TLRs: Innate Immune Sentries against SARS-CoV-2 Infection

Int J Mol Sci. 2023 Apr 29;24(9):8065. doi: 10.3390/ijms24098065.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been responsible for a devastating pandemic since March 2020. Toll-like receptors (TLRs), crucial components in the initiation of innate immune responses to different pathogens, trigger the downstream production of pro-inflammatory cytokines, interferons, and other mediators. It has been demonstrated that they contribute to the dysregulated immune response observed in patients with severe COVID-19. TLR2, TLR3, TLR4 and TLR7 have been associated with COVID-19 severity. Here, we review the role of TLRs in the etiology and pathogenesis of COVID-19, including TLR7 and TLR3 rare variants, the L412F polymorphism in TLR3 that negatively regulates anti-SARS-CoV-2 immune responses, the TLR3-related cellular senescence, the interaction of TLR2 and TLR4 with SARS-CoV-2 proteins and implication of TLR2 in NET formation by SARS-CoV-2. The activation of TLRs contributes to viral clearance and disease resolution. However, TLRs may represent a double-edged sword which may elicit dysregulated immune signaling, leading to the production of proinflammatory mediators, resulting in severe disease. TLR-dependent excessive inflammation and TLR-dependent antiviral response may tip the balance towards the former or the latter, altering the equilibrium that drives the severity of disease.

Keywords: COVID-19; SARS-CoV-2; Toll-like receptor; host genetics; innate immunity.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Cytokines
  • Humans
  • Immunity, Innate
  • SARS-CoV-2
  • Toll-Like Receptor 2*
  • Toll-Like Receptor 3
  • Toll-Like Receptor 4
  • Toll-Like Receptor 7
  • Toll-Like Receptors

Substances

  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Toll-Like Receptor 3
  • Toll-Like Receptor 7
  • Toll-Like Receptors
  • Cytokines